Cite
MLA Citation
Robert J. Motzer et al.. “Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial.” Cancer, vol. 126, no. 18, 2020, pp. 4156–4167. http://access.bl.uk/ark:/81055/vdc_100106915228.0x00005c